A Prospective Non-interventional/Observational Patient Cohort Study on the Efficacy of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients.
Observational
Observational Model: Cohort, Time Perspective: Prospective
Dose of Instanyl
Initially prescribed dose/ most efficient single dose of Instanyl at study end
during therapy with Instanyl (planned: 28 days)
No
Dr. Thomas D. Bethke, PhD; MD
Study Director
Nycomed Deutschland GmbH, 78467 Konstanz, Germany
Germany: Federal Institute for Drugs and Medical Devices
FT-1301-401-DE
NCT00994760
September 2009
November 2010
Name | Location |
---|